C K Cunningham

Summary

Affiliation: SUNY Upstate Medical University
Country: USA

Publications

  1. ncbi request reprint Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women
    C K Cunningham
    Department of Pediatrics, State University of New York, Upstate Medical University, Syracuse, NY 13210, USA
    Clin Infect Dis 32:801-7. 2001
  2. ncbi request reprint Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    Coleen K Cunningham
    Department of Pediatrics, State University of New York Upstate Medical University, Syracuse, Syracuse, NY 13210, USA
    J Infect Dis 186:181-8. 2002
  3. pmc Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA
    Marie Louise Newell
    Centre of Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, UK
    BMC Infect Dis 7:60. 2007
  4. pmc Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV
    Kristine L Witt
    National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
    Environ Mol Mutagen 48:322-9. 2007
  5. ncbi request reprint The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316
    Coleen K Cunningham
    Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    J Acquir Immune Defic Syndr 36:800-7. 2004
  6. ncbi request reprint Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316
    D Heather Watts
    National Institute of Child Health and Human Development, Bethesda, MD 20892, USA
    Am J Obstet Gynecol 190:506-16. 2004
  7. ncbi request reprint Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose
    Mark Mirochnick
    Boston University School of Medicine, Boston Medical Center, 91 Concord Street, 6th Floor, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 33:153-6. 2003
  8. ncbi request reprint Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial
    Alejandro Dorenbaum
    Department of Pediatrics, University of California, San Francisco, USA
    JAMA 288:189-98. 2002
  9. ncbi request reprint Newer treatments for HIV in children
    Ross E McKinney
    Departmentof Pedicatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Pediatr 16:76-9. 2004
  10. ncbi request reprint Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships
    Dolors Soy
    Department of Biopharmaceutical Sciences, School of Pharmacy, University of California San Francisco, San Francisco, Calif, USA
    Clin Pharmacol Ther 74:569-80. 2003

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women
    C K Cunningham
    Department of Pediatrics, State University of New York, Upstate Medical University, Syracuse, NY 13210, USA
    Clin Infect Dis 32:801-7. 2001
    ..Thus, both vaccines were safe and well tolerated in neonates, and there was no evidence of accelerated immunologic decline in HIV-infected infants...
  2. ncbi request reprint Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    Coleen K Cunningham
    Department of Pediatrics, State University of New York Upstate Medical University, Syracuse, Syracuse, NY 13210, USA
    J Infect Dis 186:181-8. 2002
    ..The risk of nevirapine resistance should be considered when determining the risks or benefits of intrapartum nevirapine in women receiving antepartum antiretroviral therapy...
  3. pmc Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA
    Marie Louise Newell
    Centre of Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, UK
    BMC Infect Dis 7:60. 2007
    ....
  4. pmc Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV
    Kristine L Witt
    National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
    Environ Mol Mutagen 48:322-9. 2007
    ..These results demonstrate that transplacentalZDV exposure is genotoxic in humans. Long-term monitoring of HIV-uninfected ZDV-exposed infants is recommended to ensure their continued health...
  5. ncbi request reprint The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316
    Coleen K Cunningham
    Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    J Acquir Immune Defic Syndr 36:800-7. 2004
    ..Race/ethnicity is significant in predicting viral suppression at the time of delivery...
  6. ncbi request reprint Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316
    D Heather Watts
    National Institute of Child Health and Human Development, Bethesda, MD 20892, USA
    Am J Obstet Gynecol 190:506-16. 2004
    ..The purpose of this study was to evaluate rates of maternal toxicity, pregnancy complications, and peripartum morbidity by type and duration of antiretroviral therapy (ART) during pregnancy...
  7. ncbi request reprint Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose
    Mark Mirochnick
    Boston University School of Medicine, Boston Medical Center, 91 Concord Street, 6th Floor, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 33:153-6. 2003
    ..To evaluate cord blood and predose nevirapine concentrations in infants exposed to the two-dose intrapartum neonatal nevirapine regimen...
  8. ncbi request reprint Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial
    Alejandro Dorenbaum
    Department of Pediatrics, University of California, San Francisco, USA
    JAMA 288:189-98. 2002
    ..However, it is unknown whether the addition of the 2-dose nevirapine regimen to standard ART would further reduce perinatal HIV transmission...
  9. ncbi request reprint Newer treatments for HIV in children
    Ross E McKinney
    Departmentof Pedicatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Pediatr 16:76-9. 2004
    ..Several new antiretroviral agents have been introduced into pediatric and adult use. This review will summarize information about these new agents and other recent advances in the care of HIV-infected children...
  10. ncbi request reprint Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships
    Dolors Soy
    Department of Biopharmaceutical Sciences, School of Pharmacy, University of California San Francisco, San Francisco, Calif, USA
    Clin Pharmacol Ther 74:569-80. 2003
    ..Our objective was to describe the population pharmacokinetics and pharmacodynamics of enfuvirtide acting on viral ribonucleic acid in children with human immunodeficiency virus 1...
  11. ncbi request reprint Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children
    Joseph A Church
    Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, CA 90027, USA
    Pediatr Infect Dis J 23:713-8. 2004
    ..The safety and antiretroviral activity of enfuvirtide treatment of 24 weeks in HIV-1-infected children has been previously documented. Here we present the long term tolerability and safety of enfuvirtide...
  12. ncbi request reprint Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials
    Daniel K Benjamin
    Department of Pediatrics, Duke University, Durham, NC, USA
    J Antimicrob Chemother 54:701-3. 2004
    ....
  13. pmc Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection
    Jennifer J Kiser
    University of Colorado at Denver and Health Sciences Center, Denver, CO, USA
    Antimicrob Agents Chemother 52:631-7. 2008
    ..Additional studies of the exposure-response relationships of this regimen in children, adolescents, and adults would advance our knowledge of its pharmacodynamic properties...